VEGFC and neoplasm: This observed decrease in metastatic spread to distant organ does not likely reflect inhibition of primary metastatic growth, as SLN tumor volumes were not consistently decreased with anti-NRP2B or anti-VEGF-C treatment (Figure 9E).